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Drosophila Crumbs has been reported to 
attenuate Notch signaling by inhibition of 
γ-secretase cleavage at the wing margins. 
γ-Secretase is an intramembrane protease that is 
responsible for the generation of amyloid-β  (Aβ) 
peptides from the β-amyloid precursor protein 
(APP). Here, we reexamined γ-secretase inhibition 
by human CRB2 that is the most abundant 
Crumbs ortholog in brain. Transfected CRB2 
inhibited proteolytic production of Aβ  and APP 
intracellular domain from APP C-terminal 
fragments in HEK293 and SH-SY5Y cells. 
Conversely, knockdown of endogenous CRB2 
increased γ-secretase cleavage products in 
SH-SY5Y cells. CRB2 inhibition of γ-cleavage was 
also detected in cell-free assays. CRB2 interacted 
with the γ-secretase complex, but was not a 
competitive substrate for γ-cleavage. The 
transmembrane domain of CRB2 was 
indispensable for inhibition of Aβ  generation, and 
mediated CRB2 binding with the γ-secretase 
complex. In addition, the cytoplasmic domain 
appeared to play a supportive role in γ-secretase 
inhibition, while mutational disruption of the two 
protein-binding motifs involved in the formation 
of cell adhesion complexes did not affect 
γ-secretase inhibition. Co-overexpression of 
presenilin-1 or APH-1 abrogated γ-secretase 
inhibition probably through prevention of the 
incorporation of CRB2 into the γ-secretase 
complex. Our results suggest that CRB2 functions 
as an inhibitory binding protein that is involved in 
the formation of a mature but inactive pool of the 
γ-secretase complex. 
 
An emerging class of intramembrane proteases 
cleaves the transmembrane (TM) domains of proteins 
within the hydrophobic environment of the 
membrane, which releases polypeptides from the 
membrane into the extracellular milieu and the 
cytoplasm (reviewed in (1-3). The liberated peptides 
possess diverse biological activities including 
transcription factor and growth factor activities. 
These cleavage events are highly regulated and serve 
as key processes of signal transduction pathways. 
γ-Secretase is a representative intramembrane 
aspartyl protease and mediates cleavage of type I 
membrane proteins such as β-amyloid precursor 
protein (APP) and Notch receptors within their 
membrane-spanning segments (4). γ-Secretase 
cleavage exhibits no or relaxed sequence specificity, 
and, to date, more than 60 transmembrane proteins 
have been described as γ-secretase substrates. It is 
known that extracellular cleavage of the substrates at 
juxtamembrane region is a prerequisite for γ-secretase 
proteolysis whether ectodomain shedding is 
constitutive or induced by ligand stimulation.  
γ-Secretase cleavage of APP is subsequent to 
ectodomain shedding that is constitutively executed 
by α-secretase and β-secretase, and releases p3 and 
amyloid-β (Aβ) peptides into the extracellular space 
and APP intracellular domains (AICD) into the 
cytoplasm. The released AICD fragments translocate 
into the nucleus and regulate the transcription of 
specific target genes. On the other hand, the 
extracellular Aβ peptide is considered a cause of 
Alzheimer's disease (AD). Thus, excessive Aβ 
peptides oligomerize to cause neuronal dysfunction 
and degeneration in the brains of AD patients 
resulting in the manifestation of severe dementia. 
γ-Secretase is a membrane-embedded, 
multimeric protein complex composed of four 
membrane proteins; presenilin (PS), nicastrin (NCT), 
APH-1 and PEN-2. Presenilins (PS1 and PS2) have a 
catalytic center, although three other components are 
required for activity. Upon assembly and activation of 
the complex, PS is endoproteolyzed into an 
N-terminal fragment (NTF) and a C-terminal 
fragment (CTF). The mechanism of intrinsic 
regulation of γ-secretase activity remains to be 
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elucidated, although some regulatory proteins have 
recently been reported. To date, many of the reported 
regulatory proteins act as inhibitors of Aβ secretion 
by distinct mechanisms. An integral membrane 
component of coatomer-coated vesicles, termed p23 
or TMP21, has dual inhibitory effects on Aβ 
generation both directly binding the γ-secretase 
complex to inhibit its activity and altering the 
trafficking of APP and/or γ-secretase complexes (5,6). 
CD147, a member of the immunoglobulin 
superfamily, has also been reported as an inhibitory 
component of γ-secretase complexes (7); however, 
contradictory results showing that CD147 did not 
alter the proteolysis of APP have been reported (8). In 
contrast, Retention in endoplasmic reticulum 1 (Rer1) 
decreases Aβ secretion through down-regulation of 
γ-secretase assembly by competing with APH-1 for 
NCT binding (9). Rer1 also binds to and retains 
unassembled PEN-2 in the ER (10). Phospholipase 
D1 has been reported to interrupt the incorporation of 
PEN-2 into γ-secretase complexes thereby inhibiting 
Aβ production (11). 
Recently, Herranz et al. (12) reported that the 
Drosophila Crumbs transmembrane protein attenuates 
Notch signaling by inhibition of γ-secretase cleavage 
of the Notch receptor at the wing margins. A well 
known function of Crumbs orthologs is to organize a 
macromolecular protein scaffold at the intracellular 
face of the membrane, which is involved in the 
maintenance of apico-basal cell polarity and adherens 
junctions (reviewed in(13). Of three human Crumbs 
orthologs, CRB2 is expressed at a higher level in the 
brain, whereas CRB1 and CRB3 are mainly 
expressed in the retina and epithelia, respectively (14). 
In this study, we examined γ-secretase inhibition by 
human CRB2 in mammalian cells and attempted to 
explore its underlying mechanism. A previous report 
failed to detect any effect of truncated CRB2 on 
γ-secretase cleavage of APP and Notch in cultured 
HEK293 cells (15). However, using overexpression 
of full-length (FL) CRB2 as well as knock-down of 
endogenous CRB2 in mammalian cells we found that 
CRB2 bound the γ-secretase complex and inhibited 
proteolytic production of Aβ and AICD. The TM 
domain of CRB2 was indispensable for this inhibitory 
activity and for binding to PS1, whereas the 
cytoplasmic domain played a supportive role in the 
inhibition. CRB2 appears to be an inhibitory binding 
protein for the γ-secretase complex but is not a 
competitive substrate. 
 
EXPERIMENTAL PROCEDURES 
 
cDNA constructs ––– A plasmid encoding FL 
human CRB2 cDNA was generated by subcloning the 
product obtained by RT-PCR of human retina mRNA 
into pBluescript II (Stratagene). For construction of a 
CRB2 expression vector without a tag, CRB2 cDNA 
was subcloned into pcDNA4 (Invitrogen). For 
construction of CRB2 with an internal Flag tag 
(CRB2-iFlag), the Flag-epitope tag sequence was 
inserted immediately downstream of the signal 
sequence (amino acid residues 1-36). CRB2 
N-terminal truncation mutants (NT1, NT2, NT3 and 
NT4) were constructed by PCR using CRB2-iFlag as 
a template. CRB2-NT5 was constructed by removing 
the Flag tag from NT4. T-CRB2 that lacks the 
N-terminal 350 residues including the signal 
sequence but has an N-terminal Flag tag was 
constructed by PCR. A TM domain chimera 
(NT5-TMC), in which the TM domain of CRB2-NT5 
was replaced with the TM domain of the human TrkB 
receptor tyrosine kinase, was generated by PCR. 
CRB2 C-terminal truncation mutants (CT1 and CT2), 
a missense mutant at the FERM (protein band 4.1, 
ezrin, radixin and moesin)-binding motif (Y1258 to A, 
P1260 to A and E1264 to A; NT4-mFERM) and a PDZ 
(PSD-95, Discs Large and ZO-1)-binding motif 
(ERLI)-deleted mutant (NT4-ΔPDZ) were generated 
by PCR-based site-directed mutagenesis. The 
expression plasmids for CRB1 and CRB3 were 
obtained from Dr. Ben Margolis (University of 
Michigan Medical School). The plasmids encoding 
PS1 and NCT have been previously described (16). 
To construct APH-1b and PEN-2 expression plasmids, 
RT-PCR products were subcloned into pcDNA3-Flag. 
Expression vectors for signal peptide peptidase-like 
protease 2b (SPPL2b) and human tumor necrosis 
factor-α (TNF-α) were constructed by subcloning 
their RT-PCR products into pcDNA4-Myc and 
pcDNA3-Flag, respectively. The sequences of all 
constructs were confirmed by sequencing. 
Antibodies and reagents ––– Anti-human CRB2 
polyclonal antibodies were raised in rabbits against 
synthetic polypeptides that were composed of the 
extracellular sequence between amino acid residues 
276 and 292 (CLQRSDPALYGGVQAAF) for 
CRB2(N1) and the cytoplasmic sequence between 
residues 1248 and 1266 with an added N-terminal 
Cys residue (C+ARKRRQSEGTYSPSQQEVA) for 
CRB2(C). Each antibody was purified with a 
peptide-conjugated affinity column. The following 
antibodies were purchased from the respective 
manufactures: mouse anti-PS1 loop and rabbit 
anti-APP CTF (Chemicon); rabbit anti-NCT (N1660), 
mouse anti-Flag tag (M2) and mouse anti-β-actin 
(Sigma); mouse anti-PS1 NTF (IBL); rabbit 
anti-APH-1 (Covance), rabbit anti-PEN-2 (Zymed), 
rabbit anti-Sec61α (Upstate), mouse anti-Flottilin-2 
(BD Biosciences), mouse anti-KDEL (Stressgen) and 
 3 
mouse anti-Myc tag (9E10) (Santa Cruz 
Biotechnology). The γ-secretase inhibitor, 
{1S-benzyl-4R-[1S-carbamoyl-2-phenylethylcarbamo
yl-1S-3-methylbutylcarbamoyl]-2R-hydroxy-5-pheny
lpentyl} carbamic acid tert-butyl ester (L685,458) 
was obtained from Calbiochem. 
Cell lines and cDNA transfection ––– HEK293 
cells stably expressing wild-type APP (HEK/wtAPP) 
or APP-SC99 (HEK/C99), and SH-SY5Y 
neuroblastoma cells stably expressing wild-type APP 
(SY5Y/wtAPP), have been previously described 
(17,18). Neuronal differentiation of SH-SY5Y cells 
was induced by treatment with 160 nM 
12-O-tetradecanoylphorbol-13-acetate (TPA) and 1 
mM dibutyryl cAMP for 7 days. cDNA transfection 
was carried out using Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacturer’s protocol. 
RNA interference ––– For small interfering RNA 
(siRNA)-mediated knockdown of human CRB2, an 
siGENOME ON-TARGETplus duplex J-0180054-07 
(CRB2-siRNA-3, 
5'-CCUAAACGAUGGCCAUUGGUU-3' (sense), 
5'-CCAAUGGCCAUCGUUUAGGUU-3' 
(antisense)) and a nontargeting control siRNA 
D-001810-05 were obtained from Dharmacon. 
SH-SY5Y cells in 6-well plates were transfected with 
125 pmol of the siRNA duplexes using Lipofectamine 
RNAi MAX (Invitrogen) according to the 
manufacture’s protocol. Culture medium was 
changed 24 h after transfection, and cells were then 
cultured for another 24 h to prepare conditioned 
medium for Aβ measurement. Cells were harvested 
48 h after siRNA transfection. 
Immunoblotting and immunoprecipitation ––– 
For immunoblotting, cells or membrane fractions 
were lysed in a lysis buffer (25 mM HEPES (pH 7.5), 
150 mM NaCl, 2 mM EDTA, Complete protease 
inhibitor cocktail (Roche Diagnostics) and 10% 
glycerol) containing 1% NP40. Immunoblotting was 
performed as previously described (19). For 
immunoprecipitation, cells or brain homogenates 
were lysed in a lysis buffer containing 1% 
3-[(3-cholamidopropyl)dimethylammonio]-2-hydrox
y-1-propanesulfonic acid (CHAPSO). After 
preclearing with protein A-Sepharose CL-4B 
(Amersham Biosciences), lysates were incubated 
with antibody for 2 h, followed by overnight 
incubation with protein A-Sepharose at 4 °C. The 
immunoprecipitates were washed 3 times with 1% 
CHAPSO buffer and subjected to immunoblotting. 
Blue native (BN) gel electrophoresis ––– BN 
polyacrylamide gel electrophoresis was performed as 
previously described (20). In brief, microsomal 
membranes were prepared and then solubilized with 
ice-cold BN-lysis buffer containing 0.7% n-dodecyl 
β-D-maltoside (DDM), 500 mM 6-aminocaproic acid, 
50 mM Bis-Tris, pH 7.0, plus Complete protease 
inhibitor cocktail. The lysate was centrifuged at 
100,000 x g for 20 min, and the supernatant was 
mixed at a ratio of 1:2 by volume with BN-sample 
buffer containing 0.75% (w/v) Coomassie brilliant 
blue G-250, 500 mM 6-aminocaproic acid, 50 mM 
Bis-Tris, pH 7.0, 30% glycerol, and 0.7% DDM. The 
samples were resolved in 6–13% BN gels, and 
transferred onto polyvinylidene difluoride membranes. 
Urease (hexamer 545 kDa, trimer 272 kDa, dimer 
132 kDa) and bovine serum albumin (66 kDa) 
(Sigma) were used as standard proteins. 
Cell-free AICD generation and AICD reporter 
assays ––– A cell-free AICD generation assay was 
carried out based on a previous report (17). Briefly, 
crude membrane fractions obtained from HEK/C99 
cells were solubilized in a lysis buffer containing 
0.5% CHAPSO and 5 mM 1,10-phenanthroline. 
Protein concentrations were determined with a 
protein DC assay kit (Bio-Rad) using bovine serum 
albumin as the standard, and were adjusted to 1 
mg/ml. After incubation for 0, 1 or 4 h at 37 °C, equal 
amounts of lysates were analyzed by immunoblotting 
with an anti-APP CTF antibody. 
For the AICD reporter assay, the GAL4 
DNA-binding domain/VP16, fused to the cytoplasmic 
tail of APP695 (APP-GV) or AICD (AICD-GV), was 
subcloned into pcDNA3 (Invitrogen). A GAL4 
reporter plasmid encoding firefly luciferase (pG5luc) 
and a plasmid encoding Renilla luciferase (pRL-TK) 
were obtained from Promega. Subconfluent HEK293 
cells in 6-well plates were transiently transfected with 
the indicated amount of DNA for each construct. To 
control for transfection efficiency, 20 ng of pRL-TK 
was added to each plasmid mix. The cells were lysed 
24 h after transfection, and firefly and Renilla 
luciferase activities were quantified using a dual 
luciferase reporter assay system (Promega) and a 
luminometer AB-2250 (Atto). Firefly luciferase 
values were standardized to the corresponding Renilla 
luciferase values. 
The Notch-ΔE reporter assay for Notch 
intracellular domain (NICD)-dependent 
transcriptional transactivation was described 
previously (21). 
Cell-free Aβ generation assay ––– The 
generation of Aβ40 and Aβ42 peptides in 
CHAPSO-solubilized γ-secretase enzyme 
preparations using an exogenous recombinant 
APP-C99-Flag substrate has been described 
previously (22). Essentially, the γ-secretase enzyme 
from HEK293 cell membranes was solubilized in a 
buffer containing 1% (w/v) CHAPSO, 50 mM 
HEPES-NaOH, pH 7.0, 150 mM NaCl, 5 mM CaCl2, 
 4 
5 mM MgCl2, and Complete protease inhibitor 
cocktail. The enzyme solution was then adjusted with 
the same buffer without CHAPSO to give a final 
detergent concentration of 0.25% CHAPSO (w/v). 
For the in vitro γ-secretase reaction, 10 µl of 
solubilized enzyme (0.6–0.7 mg/ml protein) were 
incubated for 6 h at 37 °C with the recombinant 
APP-C99-Flag substrate in the presence of 0.1% 
phosphatidyl choline in a final volume of 40 µl.  
Aβ measurement ––– The levels of Aβ40 and 
Aβ42 were measured using sandwich ELISA kits 
(WAKO Pure Chemical Industries). Each sample was 
assayed in tripricate and the values were averaged. 
The Aβ levels in the conditioned media were 
normalized to the total protein concentrations of the 
cell lysates. 
Lipid rafts isolation ––– Lipid rafts were 
isolated as described previously (23) with some 
modifications. HEK293 or SH-SY5Y cells were 
washed three times with ice-cold PBS and lysed on 
ice for 20 min in 0.5% Lubrol lysis buffer (Serva) 
supplemented with Complete protease inhibitor 
cocktail. The cell lysates were homogenized with 10 
strokes of a Dounce homogenizer and centrifuged for 
5 min at 1,000 x g at 4 °C in a microcentrifuge to 
remove insoluble material and nuclei. Lysates were 
adjusted to a final sucrose concentration of 45%, 
placed at the bottom of ultracentrifuge tubes, and 
overlaid with 6 ml of 35% and 3 ml of 5% sucrose. 
Lysates were ultracentrifuged at 4 °C in an SW41 
rotor (Beckman) for 18 h at 38,000 rpm. Twelve 1-ml 
fractions were collected from the top to the bottom 
and analyzed by immunoblotting. 
 
RESULTS 
 
Expression of CRB2 in mammalian cells and 
brains ––– To assess protein expression of CRB2, 
affinity-purified polyclonal anti-peptide antibodies, 
CRB2(N1) and CRB2(C), were generated against 
unique amino acid sequences at the extracellular and 
cytoplasmic regions respectively of human CRB2. 
Immunoblot analysis of CRB2-transfected HEK293 
cells using either of these antibodies indicated that 
CRB2 migrated as a doublet of bands corresponding 
to molecular masses of 180 and 160 kDa (Fig. 1A). 
The electrophoretic mobility of CRB2 was increased 
by digestion with either endoglycosidase H (Endo H) 
or peptide-N-glycosidase F (PNGase F). While the 
entire band of 160 kDa was completely shifted 
following either Endo H or PNGase F digestion, the 
180-kDa band was partially resistant to Endo H but 
completely sensitive to PNGase F treatment (Fig. 1B). 
This result indicated that CRB2 is posttranslationally 
modified by complex N-linked glycosylation. 
To confirm endogenous expression of CRB2 in 
mammalian brain, we immunoblotted cerebral cortex 
lysates of freshly prepared cynomolgus monkey brain 
with the CRB2(N1) antibody. This antibody 
recognized endogenous CRB2 that migrated at a 
molecular weight of approximately 180 kDa (Fig. 
1C). The specificity of this antibody was verified by 
the lack of immunoreactivity when antibody that had 
been preabsorbed with the synthetic peptide 
immunogen was used. These data indicated that the 
180-kDa band represents predominant species of 
endogenous CRB2 in mammalian brains and that the 
CRB2 expression plasmid can be used to analyze 
CRB2 cellular function. 
CRB2 suppresses Aβ secretion and AICD 
generation in cultured cell-based assays ––– Tο 
determine the effect of CRB2 on γ-secretase function 
we first assayed the effect of CRB2 expression on 
γ-secretase cleavage activity.  γ-Secretase cleaves 
APP and Notch at multiple sites; C-terminal cleavage 
releases AICD and NICD respectively into the 
cytoplasm, whereas N-terminal cleavage yields 
several Aβ and Notch-β species, respectively. We first 
confirmed that CRB2 suppresses Notch-mediated 
transcriptional activation as previously reported (12) 
using a Notch-ΔE luciferase reporter assay (Fig. 2A). 
Notch-ΔE lacks the ectodomain of Notch receptor 
and is constitutively cleaved by γ-secretase. The 
specificity of this cell-based assay for γ-secretase 
cleavage was demonstrated by treatment with a 
potent γ-secretase inhibitor, L685,458, which 
attenuated luminescence in a dose-dependent manner. 
Co-expressed CRB2 clearly decreased 
γ-secretase-dependent emission of luciferase 
luminescence but did not suppress the 
γ-secretase-independent luminescence emission 
evoked by NICD transfection. Similar results were 
obtained in an APP luciferase reporter assay (Fig. 2B). 
These results suggested that CRB2 inhibits 
γ-secretase cleavage and thereby proteolytic 
production of NICD and AICD. 
We next investigated the effect of CRB2 on Aβ 
secretion using cultured mammalian cells. When 
transfected into HEK/wtAPP cells, CRB2 decreased 
the level of secreted Aβ40 and Aβ42 (Fig. 2C). No 
difference in the degree of inhibition of Aβ40 and 
Aβ42 was observed. A similar decrease was induced 
following transfection of CRB2 into human 
neuroblastoma SY5Y/wtAPP cells and HEK/C99 
cells. The latter cell line stably expressed 
β-secretase-cleaved APP-C99, the direct substrate of 
γ-secretase. These results suggested that CRB2 
inhibition is observed in non-neuronal and neuronal 
cell lines and occurs at the level of γ-secretase 
cleavage but not at the preceding β-secretase 
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cleavage.  
To confirm the role of CRB2 in γ-secretase 
cleavage, we assayed the effect of reducing the 
cellular level of CRB2 by siRNA on Aβ secretion 
(Fig. 2D). Expression of endogenous CRB2 in 
differentiated SH-SY5Y cells, and its knockdown by 
siRNA, was confirmed by immunoblotting. 
Knockdown of CRB2 in differentiated SY5Y/wtAPP 
cells resulted in a 1.3-fold increase in secretion of 
Aβ40 and Aβ42 (Fig. 2D). To rule out the possibility 
that the increase in Aβ secretion by CRB2 
knockdown in the differentiated SY5Y/wtAPP cells 
might be somehow related to artificial overexpression 
of APP, we confirmed that a similar increase in Aβ 
occurred in differentiated native SH-SY5Y cells when 
treated with the same siRNA (data not shown). 
These results are in contradiction to a previous 
report which described that overexpression of CRBs 
did not affect Aβ production in HEK293 cells (15). 
To address this discrepancy, we examined CRB1, 
T-CRB2 and CRB3 expressing plasmids that are the 
same or similar to plasmids used in the previous 
study (Supplementary Fig. S1). Transient transfection 
with these plasmids into HEK/wtAPP cells resulted in 
significant decrease in secreted Aβ. When transfected 
into SH-SY5Y cells, all constructs but T-CRB2 
significantly decreased Aβ secretion. However, when 
transfected into HEK293 cells, the Aβ decrease was 
not statistically significant as reported (15). The 
secreted Aβ levels in native HEK293 cells were 
approximately ten times and four times less than 
those in HEK/wtAPP cells and in SH-SY5Y cells, 
respectively. We presumed that the previous study 
failed to detect a significant decrease in Aβ due to 
low level of secreted Aβ in HEK293 cells. In addition, 
signal peptide-deleted T-CRB2 decreased the Aβ 
levels less efficiently than CRB2-iFlag and 
N-terminally truncated but signal peptide-bearing 
CRB2-NT4. This suggested that deletion of the signal 
peptide perturbed the inhibitory activity. Our result 
also suggested that CRB1 and CRB3 inhibit Aβ 
generation. But we could not evaluate the inhibition 
by the endogenous proteins, because a specific 
antibody recognizing endogenous CRB1 or CRB3 is 
not available at present. 
CRB2 inhibits γ-secretase cleavage of APP in 
cell-free assays ––– We next investigated whether 
CRB2-suppression of Aβ secretion is indeed caused 
by direct inhibition of γ-secretase activity, using an in 
vitro γ-secretase assay (Fig. 2E). In this assay, a 
CHAPSO-solubilized membrane fraction of HEK293 
cells, transiently transfected with CRB2 or mock 
plasmids, was incubated with recombinant APP-C99 
at 37 °C for 6 h. This assay allowed evaluation of Aβ 
generation in cell-free conditions, under which Aβ 
generation could be specifically inhibited by the 
γ-secretase inhibitor L685,458. CRB2 transfection 
significantly inhibited Aβ production in this assay.  
To assess the inhibitory effect of CRB2 on 
cell-free production of AICD fragments, the amount 
of AICD generated from membrane fractions of 
mock- or CRB2-transfected HEK/C99 cells was 
compared by immunoblotting (Fig. 2F). Less AICD 
fragments were generated from membranes of 
CRB2-transfected cells than from membranes of 
mock-transfected cells. These results suggested that 
CRB2 indeed inhibits γ-secretase cleavage of 
APP-C99. 
CRB2 binds with the PS1/γ-secretase complex 
––– Exogenous expression of CRB2 did not alter the 
expression level of the PS1/γ-secretase complex as 
previously reported (15). To determine whether 
CRB2 directly interacts with the PS1 complex, we 
analyzed the binding between CRB2 and each 
component of the complex by 
co-immunoprecipitation assays (Fig. 3A). CRB2 was 
immunoprecipitated with the CRB2(C) antibody from 
lysates of HEK293 cells that were co-transfected with 
CRB2 and four components of the complex. In the 
transfected cells, the immature complex containing 
PS1-FL and immature NCT was accumulated. 
PS1-FL, APH-1 and immature NCT did 
co-precipitate with CRB2, while proteolyzed PS1, 
PEN-2 and mature NCT showed weak 
co-precipitation. This result suggested that CRB2 
preferentially binds to a premature PS1 subcomplex 
composed of PS1-FL, immature NCT and APH-1 in 
an overexpression condition. Under physiological 
conditions, the major pool of endogenous PS1 is 
endoproteolyzed and incorporated into the mature 
γ-secretase complex. We therefore investigated 
binding between endogenous CRB2 and γ-secretase 
complexes in a cynomolgus monkey brain lysate by 
co-immunoprecipitation. Immunoprecipitation of 
endogenous CRB2 with the CRB2(N1) antibody 
co-precipitated four components of the γ-secretase 
complex (Fig. 3B). Both FL and proteolyzed 
fragments of PS1 were co-immunoprecipitated with 
CRB2. A similar result was obtained with an 
SH-SY5Y cell lysate (data not shown). These results 
suggested that endogenous CRB2 interacts with 
mature as well as immature γ-secretase complex 
under physiological conditions. 
Reverse co-immunoprecipitation with an 
anti-PS1 loop, anti-NCT, anti-APH-1 or anti-PEN-2 
antibody, followed by immunoblotting with the 
CRB2(C) or CRB2(N1) antibody gave a background 
signal that was too high to allow for evaluation of 
specific signals. Therefore, as a second method, to 
investigate whether the γ-secretase complex contains 
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CRB2, we analyzed microsomal membrane fractions 
of cultured cells by BN gel electrophoresis in which 
protein complexes are separated according to their 
molecular size (Fig. 3C). In this analysis the mature 
form of the γ-secretase complex migrated at a 
molecular weight of approximately 500 kDa as 
indicated by PS1-, NCT-, APH-1- and 
PEN-2-immunoreactive bands. Immunoblotting for 
CRB2 indicated that transfected CRB2 in HEK293 
cells was contained in complexes of a similar 
molecular weight to the γ-secretase complex (Fig. 3C, 
lane 3). Additional incorporation of CRB2 into higher 
molecular weight complexes is consistent with 
previous studies in which CRB2 was shown to be a 
component of macromolecular cell-adhesion 
complexes (13). BN analysis using native SH-SY5Y 
cells also revealed endogenous CRB2-containing 
complexes at the similar molecular weight, although 
this band was weak (Fig. 3C, lane 1). When 
co-transfected with CRB2 and four components of 
the γ-secretase complex, CRB2(N1) antibody 
detected dense bands at the same molecular weights 
as the mature complex and the NCT-APH-1 
subcomplex (Fig. 3C, lane 4), suggesting that CRB2 
bound with the immature subcomplex as well as the 
mature complex. 
The N-terminal extracellular domain of CRB2 
is dispensable for inhibition of Aβ secretion ––– To 
define the domain within CRB2 that is required for its 
inhibitory activity, we prepared a series of N-terminal 
deletion (NT series) and C-terminal truncation (CT 
series) CRB2 mutants (Fig. 4A). To avoid potential 
functional perturbation that might arise due to 
deletion of the signal sequence or to fusion of a tag 
peptide to either terminus, a Flag-epitope tag was 
inserted immediately after the signal sequence of all 
mutants as well as of CRB2-FL. Individual constructs 
were transfected into HEK/C99 cells and their 
equivalent protein expression was confirmed by 
immunoblotting using an anti-Flag-tag antibody (Fig. 
4B). The Aβ concentrations in the conditioned media 
were then measured by a sandwich ELISA (Fig. 4C). 
Transfection of the CRB2-FL construct, or of any of 
the NT series of mutants, suppressed the level of 
secreted Aβ40 and Aβ42. However, cells transfected 
with the CT1 mutant, that lacks the TM and 
cytoplasmic domains of CRB2, secreted Aβ40 and 
Aβ42 at levels that were equivalent to those observed 
in the mock-transfected control. The CT2 mutant that 
lacked the cytoplasmic domain caused weak but 
significant attenuation of Aβ secretion. These results 
demonstrated that the N-terminal extracellular 
domain is dispensable for the inhibitory activity of 
CRB2 against Aβ production. 
The CRB2 TM domain is indispensable for 
γ-secretase inhibition and mediates CRB2 binding 
with the PS1 complex ––– The CRB2-NT4 mutant 
was more effective in suppression of Aβ secretion 
than CRB2-FL. To further delineate the inhibitory 
domain of CRB2, we tested additional mutants that 
were constructed by removing the Flag-epitope tag 
from CRB2-NT4 (named CRB2-NT5) and by 
replacing the TM domain of CRB2-NT5 with the TM 
domain of the human TrkB receptor tyrosine kinase, a 
protein that is not cleaved by γ-secretase (named 
NT5-TMC) (Fig. 5A). Inhibition of Aβ secretion by 
CRB2-NT5 was equivalent to that by CRB2-NT4, 
indicating that the Flag tag did not affect CRB2-NT4 
function. In contrast, NT5-TMC showed no 
inhibitory activity when transfected into HEK/C99 
cells, further suggesting the importance of the CRB2 
TM domain for inhibition. Inhibition of Aβ secretion 
by CRB2-FL, NT4 and NT5 was accompanied by 
intracellular accumulation of APP-C99 and APP-C83, 
that are direct substrates of γ-secretase (Fig. 5B). To 
further confirm the PS1 complex-binding domain of 
CRB2, we performed coimmunoprecipitation assays 
using lysates of the transfected cells (Fig. 5C). 
Proteolyzed PS1 coprecipitated with CRB2-FL, NT4 
and NT5 but not with CT1 or NT5-TMC. These data 
implied that the CRB2 TM domain is essential for 
binding to PS1 complex and that CRB2-PS1 complex 
binding correlates with γ-secretase inhibition. 
Efficient inhibition by CRB2 requires its 
cytoplasmic domain but not its FERM- or 
PDZ-binding motif ––– The cytoplasmic 
domain-truncation mutant CT2 also attenuated Aβ 
secretion but did so less efficiently than the FL 
protein. This result suggested that the cytoplasmic 
domain is required for efficient inhibition of 
γ-secretase activity. The CRB2 cytoplasmic domain 
contains two conserved protein-binding motifs; 
FERM- and PDZ-binding motifs. These motifs are 
required for its function in cell adhesion (24). To 
clarify whether these motifs are also involved in the 
inhibition of γ-secretase activity, we generated CRB2 
constructs mutated at these motifs by modifying the 
CRB2-NT4 mutant. The resulting mutants were: 
NT4-CT2 that lacks the entire cytoplasmic and 
extracellular domains, NT4-mFERM that harbors 
critical amino acid substitutions of three residues in 
the FERM-binding motif (Y1258 to A, P1260 to A and 
E1264 to A), and NT4-ΔPDZ that harbors a deletion of 
the PDZ-binding motif. The same mutations in CRB3 
reportedly led to a defect in tight junction 
development (24). These mutants were transiently 
transfected into HEK/C99 cells, following which 
secreted Aβ levels were evaluated by ELISA (Fig. 6). 
NT4-CT2 significantly inhibited Aβ secretion, but the 
degree of inhibition was less pronounced than that by 
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NT4. In contrast, the inhibition of Aβ secretion by 
NT4-mFERM and NT4-ΔPDZ was equivalent to that 
of NT4. The differences in the degree of Aβ 
suppression were not attributable to differences in the 
expression levels of CRB2 mutants. These results 
suggested that, in addition to the TM domain, the 
cytoplasmic domain is also required for efficient 
inhibition of Aβ secretion, and that the two conserved 
protein-binding motifs are not involved in this 
inhibition. 
CRB2 is not a competitive substrate for 
γ-secretase ––– It is still controversial whether 
γ-secretase substrates competitively inhibit each 
other’s cleavage (25-27). CRB2 is a potential 
substrate for γ-secretase, because CRB2 is a type I 
TM protein. However, CRB2(N1) antibody did not 
detect any cross-reactive band in the conditioned 
medium of cultured CRB2-transfected HEK293 cells 
(Supplementary Fig. S2A), suggesting that the 
ectodomain of CRB2 is not released into the culture 
medium. The NT4 mutant more effectively inhibits 
Aβ secretion than CRB2-FL and has a short 
extracellular domain composed of the putative signal 
sequence (36 a.a.) and the Flag tag (6 a.a.). To 
determine whether CRB2-FL and the NT4 mutant are 
substrates for γ-secretase, we assayed the effect of 
treatment with the γ-secretase inhibitor L685,458 on 
the cellular level and degradation of CRB2 and NT4 
(Supplementary Fig. S2B). L685,458 treatment of 
HEK293 cells transfected with APP caused 
accumulation of APP-CTFs which are direct 
substrates for γ-secretase. In contrast, it did not lead 
to any change in the level and degradation of 
CRB2-FL or NT4. These results suggested that CRB2 
and NT4 are not substrates for γ-secretase. 
It has previously been shown for Notch and 
APP that proteolyzed cytoplasmic fragments (NICD 
and AICD) are too unstable to be detected by 
immunoblotting of cell lysates. However, AICD 
generated by γ-secretase cleavage in a cell-free assay 
can be easily detected by immunoblotting. To confirm 
that CRB2-FL and NT4 were not cleaved by 
γ-secretase into unstable fragments that could not be 
detected by immunoblotting, we further assayed 
potential cleavage of CRB2-FL and NT4 by 
γ-secretase in a similar cell-free assay to that used for 
assay of AICD generation. Thus, 
CHAPSO-solubilized microsomal membrane 
fractions were prepared from CRB2-FL- or 
NT4-transfected cells, which were then incubated in a 
buffer containing a protease inhibitor cocktail at 
37 °C for 3 h. Immunoblotting of these reaction 
mixtures did not reveal any proteolyzed fragments 
(Supplementary Fig. S2C), again suggesting that 
CRB2 and the NT4 mutant are not cleaved by 
γ-secretase. In addition, we further tested whether 
Notch-ΔE transfection could augment the inhibitory 
effect of CRB2 on Aβ secretion. Measurement of 
secreted Aβ levels in HEK/C99 cells transfected with 
CRB2 and/or Notch-ΔE showed no additive 
inhibitory effect on Aβ secretion following 
co-transfection of Notch-ΔE with CRB2 
(Supplementary Fig. S2D). These results indicated 
that CRB2 and NT4 mutant are not competitive 
substrates for γ-secretase. 
CRB2 transfection does not detectably alter 
the subcellular localization of PS1 ––– One possible 
mechanism underlying the inhibitory activity of 
CRB2 is that CRB2 might sequester the γ-secretase 
complex away from the cellular sites or 
microdomains at which the complex meets and 
cleaves APP-C99. We investigated the effect of 
CRB2 transfection on the localization of PS1 in 
cholesterol-rich lipid raft microdomains, which have 
been implicated in γ-secretase cleavage of APP (23). 
A hydrophilic nonionic detergent Lubrol WX-based 
lysates were prepared from HEK293 cells transfected 
with mock or CRB2 plasmid, followed by 
fractionation in a discontinuous sucrose density 
gradient and immunoblotting analysis of the fractions 
for PS1 and CRB2 (Supplementary Fig. S3). 
Flottilin-2, an established marker of lipid rafts, was 
indeed predominantly concentrated in the 
detergent-insoluble fractions, while the non-raft 
marker BiP was localized in the detergent-soluble 
fractions. Transfected CRB2 was distributed in the 
detergent-soluble fractions. The distribution of PS1 
was not altered by CRB2 cotransfection. Thus, PS1 
was equivalently enriched in the detergent-insoluble 
fractions of cell lysates transfected with mock or 
CRB2 plasmid. A similar result was obtained with 
SH-SY5Y cells (data not shown). 
Co-overexpression of PS1 and APH-1 
abrogates γ-secretase inhibition by CRB2 ––– Based 
on the above results, we assumed that CRB2 is 
incorporated into the PS1/γ-secretase complex as an 
inhibitory binding protein. PS1 complex assembly is 
considered to be a highly regulated and ordered 
process. It is currently accepted that NCT and APH-1 
first form a subcomplex prior to sequential 
incorporation of PS1 and PEN-2. Association of 
PEN-2 results in a proteolytically active complex, 
which contains endoproteolyzed PS1 fragments and 
is transported from the ER to the trans-Golgi 
apparatus. It is not yet known which component of 
this complex is a direct binding partner of CRB2, 
though CRB2 appears to bind preferentially to 
premature forms of the PS1 complex (Fig. 3A). To 
clarify whether overexpression of components of the 
complex might influence the inhibitory effect of 
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CRB2, we assayed the effect of co-overexpression of 
individual core component proteins with CRB2 on 
CRB2-inhibition of γ-secretase activity. We used the 
CRB2-NT4 in this assay, because this construct was 
more effective in inhibition of Aβ secretion than 
CRB2-FL. Thus, following transient co-transfection 
of NT4 with individual protein components of the 
complex into HEK/C99 cells, Aβ levels in the 
conditioned media were measured (Fig. 7A). Neither 
co-expression of NCT nor PEN-2 with NT4 caused 
any alteration in secreted Aβ levels compared to those 
observed following co-transfection with the mock 
control. However, co-expression of PS1 or APH-1 
with NT4 almost completely abrogated inhibition of 
Aβ secretion by CRB2-NT4. Substitution of 
CRB2-FL for CRB2-NT4 gave similar results but less 
prominent differences in Aβ levels (data not shown). 
We reasoned that simultaneous overexpression 
of PS1 or APH-1 might have somehow prevented the 
incorporation of CRB2 into the γ-secretase complex. 
To test this possibility, we cotransfected HEK/C99 
cells with CRB2-NT4 and individual components of 
the γ-secretase complex, and determined the amount 
of PS1, a catalytic component of the γ-secretase 
complex, that co-precipitated with CRB2 (Fig. 7B). 
Co-expression of NT4 with PS1 did indeed increase 
the binding between these two proteins, though a 
large part of exogenous PS1 remained uncleaved and 
was not incorporated into the active γ-secretase 
complex. Co-expression of NT4 with APH-1, but not 
with NCT or PEN-2, reduced its co-precipitation with 
endogenous PS1. This result suggested that 
co-overexpression of APH-1 prevented the 
incorporation of CRB2-NT4 into the PS1 complex. 
CRB2 does not inhibit SPPL2b cleavage of 
TNF-α in a cultured-cell-based assay ––– Signal 
peptide peptidases (SPP) and SPP-like proteases 
(SPPL) belonging to an intramembrane aspartyl 
protease family, share a common consensus motif, 
GxGD, at the catalytic center with γ-secretase. 
Therefore, in spite of their opposite membrane 
topology, some γ-secretase inhibitors such as 
L685,458 are also effective for inhibition of SPP or 
SPPL cleavage (28). There is a possibility that CRB2 
is a common inhibitor for GxGD type proteases. 
SPPL2b mediates intramembrane proteolysis of 
TNF-α (29,30). TNF-α is first cleaved by the TNF-α 
converting enzyme (TACE), and the resultant 
N-terminal, membrane-bound fragment (15 kDa) is 
further cleaved at an intramembrane site by SPPL2b. 
To determine whether CRB2 inhibits SPPL2b 
cleavage of TNF-α, we transiently transfected 
HEK293 cells with SPPL2b, TNF-α and/or CRB2 
and analyzed proteolyzed fragments of TNF-α by 
immunoblotting (Supplementary Fig. S4). In the 
absence of cotransfected SPPL2b, TACE-cleaved 
N-terminal fragments of TNF-α accumulated, 
whereas co-transfection of SPPL2b markedly 
decreased accumulation of these 15 kDa fragments. 
As previously reported (30), treatment with L685,458 
enhanced accumulation of these fragments by 
inhibition of SPPL2b cleavage of TNF-α. In contrast, 
co-expression of CRB2 did not increase the 
accumulation of TACE-cleaved TNF-α fragments, 
suggesting that CRB2 does not inhibit SPPL2b 
activity. 
 
DISCUSSION 
 
In this study, we described the inhibition of 
γ-secretase cleavage of APP by human CRB2 in 
cultured mammalian cells. Our data show that 
transfected CRB2 inhibited proteolytic production of 
Aβ and AICD from APP CTFs. Conversely, 
knockdown of endogenous CRB2 increased the 
amount of γ-secretase cleavage products in SH-SY5Y 
cells. Inhibition of Aβ and AICD generation could be 
detected by either cell-based or cell-free assays. 
CRB2 bound with the γ-secretase complex through 
the TM domain, which was required for the inhibitory 
activity. In addition to the TM domain, the 
cytoplasmic domain appeared to play a supportive 
role in γ-secretase inhibition, but the FERM- and 
PDZ-binding motifs were not involved in this 
inhibition. CRB2 is a γ-secretase complex-interacting 
protein, but is not a competitive substrate for 
γ-cleavage. Overexpressed FL CRB2 decreased 
secreted Aβ levels to 70-80% of the control level, 
suggesting that CRB2 is a negative modulator of 
γ-secretase activity rather than a potent inhibitor. 
Several previous studies failed to identify 
CRB2 as a component of the γ-secretase complex 
(reviewed in(31). We speculate that one or more of 
the following reasons may explain this failure: (1) 
Since CRB2 is only expressed in specific organs or 
cell lines, γ-secretase complexes isolated from 
another source would not contain the CRB2 protein. 
(2) Since CRB2 is probably not incorporated into 
100% of the γ-secretase complexes, the level of 
CRB2 co-purified with the complexes may not have 
been high enough for detection. (3) It is sometimes 
difficult to detect and identify high molecular weight 
proteins such as CRB2. (4) Since CRB2 is a negative 
regulator of γ-secretase activity, activity-dependent 
isolation of the γ-secretase complex might result in 
failure to co-purify CRB2.  
The major cellular pool of CRB family 
proteins resides at cell-cell contact sites at which it 
forms macromolecular complexes with Pals1 and 
PATJ through PDZ-binding motifs, with EPB41L5 
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and MPP5 through FERM-binding motifs, and where 
it also further interacts with other proteins (13). The 
conserved C-terminal region harboring the two 
protein-binding motifs is essential for CRB function 
during tight junction development (24,32). Similarly, 
we found that the C-terminal, TM and cytoplasmic 
domains of CRB2 were required for inhibition of 
γ-secretase cleavage of APP. However, our results 
suggest that the FERM- and PDZ-binding motifs are 
not involved in its inhibitory activity. Therefore, the 
γ-secretase inhibitory activity of CRB2 is considered 
to be independent of its well-studied function in cell 
adhesion and polarity determination.  
Our data suggested that CRB2 neither 
sequestered the γ-secretase complex away from 
subcellular domains rich in its APP-CTF substrates 
nor functioned as a competitive substrate for 
γ-secretase. Instead our results support the hypothesis 
that CRB2 interacts with the PS1/γ-secretase complex 
as an inhibitory binding protein. Co-overexpression 
of CRB2 with either PS1 or APH-1 attenuated CRB2 
suppression of Aβ secretion. Furthermore, 
co-immunoprecipitation assays showed that 
co-expressed APH-1 reduced the amount of CRB2 
bound to endogenous PS1. One possible explanation 
of these data is that CRB2 binds with PS1 and APH-1 
and that heterodimer formation between CRB2 and 
co-overexpressed PS1 or APH-1 precludes 
incorporation of CRB2 into the maturing γ-secretase 
complex, thereby preventing CRB2 from acting as an 
inhibitory binding protein. In contrast, when 
cotransfected with CRB2 and NCT, the CRB2-NCT 
dimers could be incorporated into the complexes to 
exert the inhibitory activity. Since the γ-secretase 
complex assembly is considered to be a highly 
regulated and ordered process, it can be envisaged 
that the CRB2-PS1 and CRB2-APH-1 dimers may 
preclude incorporation of CRB2 into the complexes 
but that the CRB2-NCT dimer may not. A second 
possibility is that CRB2 binds with NCT and that 
excessive PS1 or APH-1 mitigated CRB2 inhibition 
by competing with CRB2 for binding with NCT in 
the maturing γ-complex. Since NCT has been 
reported to directly bind with both PS1 and APH-1, it 
is possible that CRB2 could compete with PS1 and 
APH-1 for binding with NCT in the maturing 
γ-secretase complex (10,33-35).  
It remains to be elucidated whether CRB2 
exhibits a constitutive or at least partially inducible 
expression in mammalian brains. Herranz et al. (12) 
showed that Crumbs expression is induced by Notch 
activation and provides a negative feedback for Notch 
signaling at Drosophila wing margins. However, we 
could not reproduce CRB2 induction by exogenously 
expressed Notch-ΔE or by NICD in cultured 
SH-SY5Y neuroblastoma cells (data not shown). A 
recent report showed that γ-secretase activity in brains 
is altered during aging, and this change could confer a 
risk for sporadic AD in aged subjects (36). A 
reduction of CRB2 expression might lead to 
insufficient inhibition of γ-secretase activity, which 
could enhance Aβ generation in human brains and 
play a causative role in the development of AD. It is a 
future issue to investigate whether the inhibition by 
CRB2 is involved in a variable fine-tuning of cellular 
γ-secretase activity in vivo and whether CRB2 
expression is reduced in aged brains and/or brains of 
patients with AD.  
Several lines of data suggest that APP-C99 is 
processed by γ-secretase activity mainly at the plasma 
membrane or in endocytotic compartments, though a 
major pool of the γ-secretase complex resides at early 
secretory compartments (37,38). On the other hand, 
previous reports (39,40) estimated that only a small 
portion of the total proteolyzed PS1 fragments in 
cellular membranes is engaged in active γ-secretase 
complexes. The results in these reports indicate that 
the major cellular pool of the PS complex is the 
mature proteolyzed form but remains catalytically 
inactive. Inhibitory binding proteins such as CRB2 
may contribute to the formation of an inactive pool of 
γ-secretase complexes by binding with a subset of the 
complex. Previous studies have shown that Aβ levels 
in brains can be reduced by decreasing γ-secretase 
activity (reviewed in(41). Therefore, an exact 
understanding of the mechanism by which cellular 
γ-secretase activity is negatively regulated might 
provide the basis for a novel therapeutic strategy for 
AD other than development of direct inhibitors of 
γ-secretase.  
γ-Secretase/PS complexes interact with many 
cell-cell and cell-matrix adhesion proteins and are 
involved in synapse formation/remodeling in brains. 
PS complexes bind to adhesion proteins such as 
telencephalin and CRB2, whereas γ-secretase cleaves 
many membrane proteins including nectin-1α and 
ephrin receptors (reviewed in(42). In particular, N- 
and E-cadherins serve as both binding partners and 
protease substrates of γ-secretase (43,44). Although it 
remains unresolved how synaptic plasticity is 
orchestrated, dysfunction of γ-secretase/PS 
complexes could cause synaptic dysregulation, 
eventually leading to neurodegeneration (45). 
Additionally, γ-secretase complex-interacting 
adhesion proteins such as N-cadherin and CRB2 are 
simultaneously involved in the regulation of cellular 
Aβ secretion (46)and this paper).  
Many clinical mutations of CRB1 cause retinal 
degeneration including autosomal recessive retinitis 
pigmentosa, Leber congenital amaurosis and 
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autosomal dominant pigmented paravenous 
chorioretinal atrophy, though the exact underlying 
pathological mechanism remains unresolved (47). 
Future studies are required to determine whether a 
dysfunction of CRB2 plays a role in the pathogenesis 
of AD.  
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FIGURE LEGENDS 
 
FIGURE 1. Expression and characterization of the human CRB2 protein. 
A, Immunoblots of transfected human CRB2. Blots of HEK293 cells transfected with CRB2 or mock plasmids 
were probed with N-terminal, CRB2(N1) (left) or C-terminal, CRB2(C) (right) antibodies. B, Glycosylation of 
CRB2. CRB2-transfected HEK293 cell lysates were treated with vehicle (Control), endoglycosidase H (Endo H) or 
peptide-N-glycosidase F (PNGase F) for 1 h at 37 °C. The blot was probed with CRB2(N1). C, Immunoblot of 
endogenous CRB2 in monkey brain. CRB2-transfected cell lysate was loaded as a size marker. The blot was probed 
with CRB2(N1) (left) or CRB2(N1) preabsorbed with the synthetic peptide immunogen (right). Asterisks in A - C 
indicate nonspecific bands. 
 
FIGURE 2. CRB2 suppresses Aβ secretion and AICD generation. 
A and B, Luciferase reporter assays of γ-secretase cleavage of Notch-ΔE (A) and APP (B). HEK293 cells in 6-well 
plates were transiently transfected with the indicated combinations of expression- and mock (m)-plasmids. Eight 
hours after transfection, the culture media were replaced by DMEM/10% fetal bovine serum containing the 
indicated concentration of the γ-secretase inhibitor L685,458. Luciferase activity was analyzed 24 h 
post-transfection as described in Experimental Procedures. Relative luciferase activity is expressed as -fold 
activation (relative to the level of a reporter gene in the presence of Notch-ΔE or APP-GV after normalization with 
co-transfected Renilla luciferase activity). The values shown are the mean ± SD for three experiments. C, Aβ 
secretion from CRB2-transfected cells. Mock- or CRB2-expression plasmids were transiently transfected into 
HEK/wtAPP cells, and Aβ40 and Aβ42 levels in the conditioned media were measured by ELISA. *p < 0.01 versus 
the Mock control by an unpaired, two-tailed Student’s t-test. The expression level of CRB2 was determined by 
immunoblotting of the cell lysates (right). D, Aβ secretion from CRB2-knockdown cells. Differentiated 
SY5Y/wtAPP cells were transfected with a control siRNA duplex or with a CRB2-targeted siRNA duplex (CRB2 
k/d), and Aβ levels in the conditioned media were measured by ELISA. *p < 0.01 versus the Control. The 
RNAi-mediated knockdown for CRB2 was confirmed by immunoblotting of the cell lysates (right). E, A cell-free 
assay of Aβ generation. Membrane fractions from HEK293 cells transfected with mock- or CRB2-plasmids were 
solubilized in CHAPSO-lysis buffer, and then incubated with a recombinant C99-Flag substrate for 6 h at 37 °C in 
the presence or absence of L685,458. Aβ levels were measured by a sandwich ELISA. *p < 0.01 versus the Mock 
control. F, A cell-free AICD generation assay. Crude membrane fractions obtained from HEK/C99 cells were 
solubilized in 0.5% CHAPSO-lysis buffer containing 5 mM 1,10-phenanthroline. Protein concentrations were 
determined and adjusted to 1 mg/ml. After incubation for 0, 1 or 4 h at 37 °C, equivalent amounts of lysates were 
subjected to immunoblotting and probed with the anti-APP CTF antibody. The graph below shows the relative 
density of the AICD bands (mean ± SD from three experiments). 
 
FIGURE 3. CRB2 binds the PS1 complex. 
A, Co-immunoprecipitation assays of transfected CRB2. CRB2-iFlag was co-transfected with PS1, NCT, APH-1 
and PEN-2 into HEK293 cells, and the expressed CRB2 was then precipitated from cell lysates with the CRB2(C) 
antibody. Precipitation with rabbit IgG was used as a negative control. The precipitates were subjected to 
immunoblotting with anti-Flag, anti-PS1 loop, anti-NCT, anti-APH-1 or anti-PEN-2 antibodies. Images of long 
exposed films are also shown for PS1-CTF, NCT and PEN-2 (long). B, Co-immunoprecipitation assays of 
endogenous CRB2. CRB2 was precipitated from lysates of monkey brain with CRB2(N1) antibody. The precipitate 
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was analyzed by immunoblotting with anti-PS1 loop, anti-NCT, anti-APH-1 or anti-PEN-2 antibodies. Precipitation 
with rabbit IgG and immunoblotting with antibody against Sec61α, an unrelated membrane protein, were used as 
negative controls. C, BN gel electrophoresis for CRB2. Microsomal membranes prepared from SH-SY5Y cells 
(lane 1), non-transfected HEK293 cells (lane 2), CRB2-NT4-transfected HEK293 cells (lanes 3, 5-8) and HEK293 
cells co-transfected with CRB2-NT4 and γ-secretase components (lane 4) were solubilized with BN-lysis buffer 
containing 0.7% DDM. The cleared lysate was analyzed by BN electrophoresis, and the blots were probed with 
CRB2(N1), anti-PS1 NTF, anti-NCT, anti-APH-1 or anti-PEN-2 antibodies. Asterisk and sharp sign indicate the 
mature form of the γ-secretase complex and the NCT-APH-1 subcomplex, respectively. 
 
FIGURE 4. CRB2 extracellular domain is dispensable for inhibition of Aβ secretion. 
A, Scheme of the CRB2 mutants. The large extracellular region of full-length (FL) CRB2 contains epidermal 
growth factor-like (EGF) domains and laminin A globular domain-like (LAG) repeats. SS and TMD represent the 
signal sequence and transmembrane domain, respectively. FL and all mutant CRB2 constructs have the N-terminal 
signal sequence followed by an inserted Flag-epitope tag. B, The expression of transfected CRB2 constructs. The 
cell lysates were immunoblotted with anti-Flag antibody (upper panel). The blot was reprobed with anti-β-actin 
antibody as a loading control (lower panel). C, Aβ secretion from mutant CRB2-transfected cells in B. Mock- or the 
indicated mutant CRB2-plasmid was transiently transfected into HEK/C99 cells, and Aβ levels in the conditioned 
media were measured by a sandwich ELISA specific for Aβ40 and Aβ42. The error bars represent the SD. *p < 
0.01 versus the Mock control by an unpaired t-test.  
 
FIGURE 5. CRB2 TM domain mediates CRB2-inhibition of Aβ secretion and CRB2-PS1-binding. 
A, Aβ secretion from mutant CRB2-transfected cells. Mock- or the indicated mutant CRB2-plasmid was transiently 
transfected into HEK/C99 cells, and Aβ40 and Aβ42 levels in the conditioned media were measured by ELISA. 
CRB2-NT5 corresponds to Flag tag-deleted CRB2-NT4, and NT5-TMC is a TM domain chimera in which the TM 
domain of CRB2-NT5 was replaced with the TM domain of the human TrkB receptor tyrosine kinase. Values are 
the mean ± SD. *p < 0.01 versus the Mock control by an unpaired t-test. B, The cell lysates in A were 
immunoblotted with an anti-APP CTF antibody. The APP cleavage products C99 and C83 are indicated. C, The cell 
lysates in A were immunoprecipitated with the CRB2(C) antibody, and the precipitates were immunoblotted with 
the anti-PS1 loop antibody (top panel). The same cell lysates (Input) were immunoblotted with anti-PS1 loop (2nd 
panel), CRB2(N1) (3rd panel), CRB2(C) (4th panel) and anti-β-actin antibody (bottom panel). The sample order in 
B and C is the same as in A. 
 
FIGURE 6. Efficient inhibition of Aβ secretion requires the CRB2-cytoplasmic domain, but not the FERM- or 
PDZ-binding motifs. 
Aβ secretion from mutant CRB2-transfected cells. Mock- and the indicated mutant CRB2-plasmids were 
transiently transfected into HEK/C99 cells, and Aβ40 and Aβ42 levels in the conditioned media were measured by 
ELISA. NT4-CT2 lacks the entire cytoplasmic and extracellular domain. NT4-mFERM harbors amino acid 
substitutions of three critical residues in the FERM-binding motif, and NT4-ΔPDZ harbors a deletion of the 
PDZ-binding motif. Values are the mean ± SD. *p < 0.01 versus the Mock control by an unpaired t-test. The protein 
expression was confirmed by immunoblotting the total cell lysates with anti-Flag antibody (upper and middle 
panels). The blot was reprobed with anti-β-actin antibody as a loading control (lower panel). 
 
FIGURE 7. Co-overexpression of PS1 or APH-1 abrogates γ-secretase inhibition by CRB2. 
A, Aβ secretion from HEK/C99 cells co-transfected with CRB2-NT4 and individual components of the γ-secretase 
complex. CRB2-NT4 was transiently co-transfected with mock, PS1, APH-1, NCT or PEN-2 plasmids into 
HEK/C99 cells, and the culture media were changed 24 h post-transfection. The cells were then cultured for a 
further 24 h, and Aβ40 and Aβ42 levels in the conditioned media were measured by ELISA. Values are the mean ± 
SD. *p < 0.01 versus the Mock-transfected control by an unpaired t-test. B, The cell lysates in A were 
immunoprecipitated with the CRB2(C) antibody and the precipitate was immunoblotted with the anti-PS1 loop 
antibody (top panel). Cell lysates were immunoblotted with an anti-PS1 loop (2nd panel), anti-APH-1 (3rd panel) 
or CRB2(C) antibody (4th panel). The graph below shows the relative density of the bands for PS1-CTF 
co-precipitated with CRB2 (mean ± SD from three experiments). Values are the mean ± SD. *p < 0.01 versus the 
NT4 + mock-transfected control by an unpaired t-test. The sample order in B is the same as in A. 







